



- (51) **International Patent Classification:**  
*A01N 55/08* (2006.01) *A61K 31/69* (2006.01)
- (21) **International Application Number:**  
PCT/US2012/051349
- (22) **International Filing Date:**  
17 August 2012 (17.08.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
61/524,429 17 August 2011 (17.08.2011) US  
61/526,787 24 August 2011 (24.08.2011) US
- (71) **Applicant (for all designated States except US):** **GLAXO-SMITHKLINE LLC** [US/US]; One Franklin Plaza, 200 North 16th Street, Philadelphia, Pennsylvania 19102 (US).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** **WALKER, Jill** [US/US]; c/o GlaxoSmithKline, Global Patents, Five Moore Drive, P.O. Box 13398, Research Triangle Park, North Carolina 27709 (US). **VOITENLEITNER, Christian** [DE/US]; c/o GlaxoSmithKline, Global Patents, Five-MooreDrive, P.O.Box13398, Research Triangle Park, North Carolina 27709 (US).
- (74) **Agents:** **THOMAS, Robert (Steve)** et al.; c/o GlaxoSmithKline, Global Patents, Five Moore Drive, P.O. Box 13398, Research Triangle Park, North Carolina 27709 (US).
- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

**Published:**

- with international search report (Art. 21(3))

(54) **Title:** THERAPEUTIC METHODS

(57) **Abstract:** The present invention features a method for the treatment of Hepatitis C in a human in need thereof comprising administering a compound of Formulas (II) or (IIB) described herein or a pharmaceutically acceptable salt thereof in combination with one or more alternative Hepatitis C therapeutic agents

